Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 3/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12595865 | 0.94 | RAD52 (0.44) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595849 | 0.89 | LMNA (0.48) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595842 | 0.88 | HRH3 (0.43) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595850 | 0.88 | HRH3 (0.43) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595816 | 0.87 | LMNA (0.51) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595911 | 0.87 | LMNA (0.41) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595833 | 0.86 | LMNA (0.50) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595747 | 0.86 | LMNA (0.50) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595742 | 0.85 | LMNA (0.49) | LMNAMEN1KMT2APDE4APDE4B | |
| SCHEMBL12595904 | 0.85 | LMNA (0.49) | LMNAMEN1KMT2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212146-B2 | Substituted pyridazinones for the treatment of tumors | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-15 | — | — | US | disclosed |
| US-20130281426-A1 | PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 2013-10-24 | — | — | US | disclosed |
| US-8501731-B2 | Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-08-06 | — | — | US | disclosed |
| US-20110112061-A1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112061-A1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | PDXK, PNPO, HCCS | LMNA 109/4885MEN1 424/4885KMT2A 1440/4885 |
| US-20130281426-A1 | PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF | CYP3A5, PDXK, HCCS | LMNA 89/4885MEN1 448/4885KMT2A 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.